170 results on '"Risse, Marie-Laure"'
Search Results
2. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
3. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
4. Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis
5. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis
6. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
8. MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis
9. MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma
10. MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis
11. POSTER: MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis
12. MM-248 Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+ Status: Updated Results from the Phase 3 IKEMA Study
13. OA-48 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
14. POSTER: MM-248 Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+ Status: Updated Results from the Phase 3 IKEMA Study
15. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis
16. P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
17. P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
18. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study.
19. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
20. Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
21. Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis
22. Poster: MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis
23. UPDATED PROGRESSION-FREE SURVIVAL (PFS) AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE (ISA-KD) VS KD IN RELAPSED MULTIPLE MYELOMA (MM)
24. Poster: MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma
25. Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
26. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
27. OAB-046: Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
28. P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
29. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
30. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
31. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
32. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
33. P-198: Isatuximab plus Carfilzomib and Dexamethasone in East Asian patients with relapsed Multiple Myeloma: IKEMA subgroup analysis
34. P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis
35. P-196: Isatuximab plus Carfilzomib and Dexamethasone in patients with relapsed Multiple Myeloma and soft-tissue Plasmacytomas: IKEMA subgroup analysis
36. Poster: MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
37. MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis
38. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
39. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
40. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis
41. The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma
42. Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
43. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
44. Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
45. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
46. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
47. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
48. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis
49. Novel Taxanes: Cabazitaxel Case Study
50. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.